	US 11,696,957 B2
	Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
Changjun Yu, Pasadena, CA (US)
Assigned to Sunstate Biosciences, LLC, Pasadena, CA (US)
Filed by Sunstate Biosciences, LLC, Pasadena, CA (US)
Filed on Oct. 14, 2019, as Appl. No. 16/601,333.
Claims priority of provisional application 62/746,964, filed on Oct. 17, 2018.
Prior Publication US 2020/0121804 A1, Apr. 23, 2020
Int. Cl. A61K 31/136 (2006.01); A61K 47/68 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01)

CPC A61K 47/6803 (2017.08) [A61K 31/136 (2013.01); A61K 31/337 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 47/643 (2017.08); A61K 47/6809 (2017.08); A61K 47/6835 (2017.08); A61P 35/00 (2018.01)]

3 Claims

1. A composition, comprising a single protein selected from the group consisting of an albumin, a globulin, and a fibrinogen, having tightly bound therein, a plurality of molecules of doxorubicin.